JHS Sven.Lab. Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what JHS Sven.Lab. management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what JHS Sven.Lab. management said on order book — free account, 30 seconds.
Capex plans
Track JHS Sven.Lab. — get its next earnings analysis in your feed
How does JHS Sven.Lab. rank vs peers in Personal Products?
Pro featureHow does JHS Sven.Lab. rank in Personal Products?
Compare JHS Sven.Lab. against every Personal Products company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What JHS Sven.Lab.'s management said in earlier quarters
Others in Personal Products this season
- Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
- Recode Studios Ltd (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
- Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
- Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag